Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alfuzosin in pediatric neurogenic bladder
NCT00549939Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2007
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial of alfuzosin in neurogenic bladder (4 arms), sponsored by Sanofi. Primary endpoint: Number of Patients With Detrusor Leak Point Pressure (LPP) < 40 cm H2O at 12 weeks. Started Oct 2007; status: completed.
02
Drugs
alfuzosin
03
Conditions
neurogenic bladder
Beyond the preview
Go deeper on NCT00549939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00549939.